PTP||How to communicative CV death and hospitalization of heart failure risk redution benefits effectively to T2D patients?

backArrow Back
organProtectonlogo

HEART

How to communicative CV death and hospitalization of heart failure risk redution benefits effectively to T2D patients?

video previous buttonPrevious video play buttonPlay video next buttonNext

EXPERTS GROUP

Prof. Sarah Jarvis

Member of British Empire, General Practitioner Visiting Professor of General Practice, University of Huddersfield

HEART
Why having CV death risk reduction benefit is important in T2D management?
701 days
HEART
What does data for SGLT2i in HF regardless of EF mean for Endocrinologists / primary care practitioners?
710 days
HEART
HF is often undiagnosed, what does HF indication mean for the use of SGLT2i in T2D?
750 days
PC-SSK-101710